Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas

Shandong University

Status: Completed

Conditions: Infantile Haemangiomas

Treatments: Drug: propranolol

Study type: Observational

Funder types: Other

Identifiers

NCT04651049

LiuSH

Details and patient eligibility

About

This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.

Enrollment: 128 patients

Sex: All

Ages: 2 to 54 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• IHs diagnosed by medical history and physical examination
• no previous treatment with other medications

Exclusion criteria

• a history or risk of asthma, reactive airway disease, impaired renal or liver function, heart defects or arrhythmia, hypotension and hypersensitivity to propranolol
• Infants who did not adhere to the treatments or attend follow-up visits
• Infants with other known risk factors for developmental delay or growth restriction, such as prematurity, small for gestational age, or other major congenital malformations, were also excluded
• No other treatment was used during the oral propranolol course

Trial design

128 participants in 1 patient group

Propranolol treatment group

Treatment:

Drug: propranolol